Editas Medicine Inc (NASDAQ:EDIT) CFO Andrew A. F. Hack sold 14,649 shares of Editas Medicine stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $24.68, for a total transaction of $361,537.32. Following the transaction, the chief financial officer now owns 5,000 shares in the company, valued at approximately $123,400. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Editas Medicine Inc (NASDAQ:EDIT) opened at $24.89 on Thursday. The company has a quick ratio of 10.12, a current ratio of 10.12 and a debt-to-equity ratio of 0.19. Editas Medicine Inc has a 52 week low of $13.12 and a 52 week high of $31.81.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.04). Editas Medicine had a negative net margin of 1,127.03% and a negative return on equity of 70.19%. The company had revenue of $6.28 million for the quarter, compared to analyst estimates of $2.66 million. During the same quarter in the previous year, the company posted ($0.59) EPS. The company’s revenue for the quarter was up 553.0% compared to the same quarter last year. sell-side analysts forecast that Editas Medicine Inc will post -2.92 earnings per share for the current year.

A number of research firms recently weighed in on EDIT. Zacks Investment Research cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Cann restated a “hold” rating on shares of Editas Medicine in a research note on Tuesday, November 7th. Morgan Stanley restated an “equal weight” rating and set a $28.00 target price (up previously from $27.00) on shares of Editas Medicine in a research note on Friday, October 6th. Barclays began coverage on shares of Editas Medicine in a research note on Wednesday, September 6th. They set an “overweight” rating and a $28.00 target price on the stock. Finally, Cowen restated a “buy” rating on shares of Editas Medicine in a research note on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $26.73.

A number of institutional investors have recently modified their holdings of EDIT. State Street Corp increased its stake in Editas Medicine by 305.4% during the 2nd quarter. State Street Corp now owns 537,640 shares of the company’s stock valued at $9,022,000 after purchasing an additional 405,022 shares in the last quarter. American Century Companies Inc. acquired a new position in Editas Medicine during the 3rd quarter valued at approximately $7,497,000. Ark Investment Management LLC increased its stake in Editas Medicine by 121.9% during the 2nd quarter. Ark Investment Management LLC now owns 510,187 shares of the company’s stock valued at $8,561,000 after purchasing an additional 280,265 shares in the last quarter. Northern Trust Corp increased its stake in shares of Editas Medicine by 245.9% in the second quarter. Northern Trust Corp now owns 373,149 shares of the company’s stock worth $6,261,000 after acquiring an additional 265,273 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Editas Medicine by 12.5% in the second quarter. Vanguard Group Inc. now owns 2,177,146 shares of the company’s stock worth $36,533,000 after acquiring an additional 241,973 shares during the period. Institutional investors and hedge funds own 65.74% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Andrew A. F. Hack Sells 14,649 Shares of Editas Medicine Inc (EDIT) Stock” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/21/andrew-a-f-hack-sells-14649-shares-of-editas-medicine-inc-edit-stock.html.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.